Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC
  • USA - English


News provided by

Wright & Schulte LLC

Dec 21, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Study Shows Low Testosterone Therapy Drugs Linked To Colon Cancer
Study Shows Low Testosterone Therapy Drugs Linked To Colon Cancer
Youtube
Youtube

Testosterone Therapy Drugs Such As AngroGel and Androderm Have Been Reportedly Linked To Heart Attacks, Strokes, and Colon Cancer

Post this

Columbus, OH (PRWEB) December 21, 2014 -- As testosterone therapy lawsuit filings on behalf of men alleging heart attacks, stroke and blood clots from using testosterone products such as AndroGel and Androderm, continue to increase, a new study shows that the male hormone testosterone may increase the risk of men developing colon cancer. In a study published in the Proceedings of the National Academy of Sciences in November, lead researcher, James Amos-Landgraf examined a group of male rats with naturally occurring colon cancer. Dr. Amos-Landgraf, an assistant professor of veterinary pathobiology at the University of Missouri College of Veterinary Medicine, then removed testosterone from the rats and the colon cancer rates drastically decreased. When he placed the testosterone back into the rats, the colon cancer rates returned to normal. Dr. Amos-Landgraf, in a news release, said,“by showing that removing testosterone from rats leads to a drastic decrease in colon cancer susceptibility, it appears that male hormones may actually contribute to colon tumor growth rather than female hormones being protective.” Dr. Amos-Landgraf added that post-menopausal women are more susceptible to colon cancer due to the increase of their testosterone levels. Female hormones, such as estrogen, which help to protect against diseases, decreases after menopause. There are currently over 270 testosterone therapy lawsuits pending litigation in Illinois that contend men taking the low testosterone treatment drugs such as AndroGel, Androderm, Testim and other Low-T medicines caused them to suffer heart attacks, strokes, and other cardiac events. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)
[pnas.org/content/111/46/16514, November 18, 2014][munews.missouri.edu/news-releases/2014/1210-testosterone-may-contribute-to-colon-cancer-tumor-growth/, December 10, 2014]

Men who suffer from low hormone testosterone are prescribed testosterone replacement therapy products to boost their natural testosterone levels. The U.S. Food and Drug Administration (FDA) has approved testosterone products to treat hypogonadism, which is low testosterone levels in men due to an underlying medical condition. However, the FDA announced in January that it is re-evaluating the safety and effectiveness of testosterone replacement therapy products after reviewing two observational studies. The first study the FDA reviewed was published in the November 2013 Journal of the American Medical Association. The study found that older men who had underlying cardiovascular disease and took testosterone replacement therapy had a 30 percent increased risk of having a stroke, heart attack or death compared to men who did not take low testosterone treatment. The second study the FDA reviewed was published in the PLOS One Journal in January 2014. This study found that men over 65 and younger men with a pre-existing heart disease were at a greater risk of having a heart attack within the first 90 days after taking low testosterone drugs for the first time. [fda.gov/Drugs/DrugSafety/ucm383904.htm, January 31, 2014] [fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ [plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0085805, January 29, 2014]
[jama.jamanetwork.com/article.aspx?articleid=1764051, November 6, 2013]

Wright & Schulte LLC is offering free legal consultations for men who used testosterone drugs such as AndroGel and Androderm and contend they experienced severe and life-threatening side effects such as heart attacks or strokes during their treatment. To learn more about filing a low testosterone therapy lawsuit, contact the attorneys at Wright & Schulte by visiting yourlegahelp.com or calling 1-800-399-0795.

As part of its investigation into FDA-approved testosterone products, the federal agency convened a meeting in September of its Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss the safety testosterone products. The two panels recommended that the FDA restrict the population of men who should be given prescription testosterone drugs, including men who have problems with low energy, low libido and other issues associated with aging, according to a New York Times report. The panels also recommended the FDA require manufacturers of testosterone drugs conduct new trials to assess the cardiovascular risks of associated with their testosterone products. According to Bloomberg, use of testosterone products such as AndroGel and Axiron doubled from 2010 to 2013 when 2.3 million men were prescribed testosterone treatment medication.
[nytimes.com/2014/09/18/health/testosterone-drugs-fda.html?_r=0, September 17, 2014] [bloomberg.com/news/2014-09-17/testosterone-drugs-may-need-further-study-on-heart-risk.html, September 18, 2014]

Testosterone lawsuits filed on behalf of men, or their survivors, who allege that they used testosterone replacement products such as AndroGel, Androderm and Testim and experienced side effects including heart attack, blood clots, strokes and death were consolidated in June for pretrial proceedings in the U.S. District Court, Northern District of Illinois. According to the court’s master case list, 274 testosterone lawsuits are pending in the multidistrict litigation as of December 15. The lawsuits name six testosterone manufacturers including AbbVie, Actavis Pharma, Auxilium Pharmaceutical, Eli Lilly & Company, Endo Pharmaceuticals Inc., and their subsidiaries as defendants. The testosterone complaints purport that the testosterone manufacturers failed to warn doctors who prescribe the medication and their patients about the potential cardiovascular risks associated with testosterone products. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright Schulte LLC stand up for the rights of people who have been injured or wronged, and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free testosterone lawsuit case evaluations are available through yourlegalhelp.com, or call 1-888-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795http://www.yourlegalhelp.com

Richard Schulte, Wright & Schulte LLC, http://yourlegalhelp.com/, +1 1-800-399-0795, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.